|
시장보고서
상품코드
2091184
궤양성 대장염 시장 규모, 점유율, 성장 분석 : 약물 계열별, 질환 중증도별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Ulcerative Colitis Market Size, Share, and Growth Analysis, By Drug Class, By Disease Severity Range, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 궤양성 대장염 시장 규모는 2024년에 95억 7,000만 달러로 평가되었으며, 2025년 103억 9,000만 달러에서 2033년까지 200억 6,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 8.57%로 성장할 것으로 전망됩니다.
세계 궤양성 대장염 시장은 많은 환자에게 영향을 미치는 이 만성 염증성 장질환의 치료를 목적으로 하는 의약품, 진단약 및 지원 서비스의 판매를 포괄합니다. 유병률의 상승, 고액의 치료비, 그리고 미충족 의료 수요가 시장의 중요성을 높이고 있습니다. 발병률의 증가는 주로 도시 지역의 생활 방식, 식생활의 변화, 그리고 인구 고령화의 영향을 받고 있습니다. 내시경 영상 진단 및 바이오마커 분석과 같은 진단 기술의 발전으로 인해 사례 탐지 정확도가 향상되었으며, 임상의들 사이에서는 기존의 스테로이드제보다 생물학적 제제를 우선적으로 사용하는 경향이 강해지고 있습니다. 경구용 저분자 약물의 등장은 더 많은 치료 선택지를 제공하고, 환자의 접근성을 높이는 동시에, 정맥 주사로 인한 부담을 줄여주고 있습니다. 또한, AI를 활용한 진단 기술은 조기 발견과 맞춤형 치료를 촉진하여 보다 효과적인 의사결정과 치료 성과 향상의 가능성을 높이고 있으며, 이를 통해 시장의 성장과 확장 전략에 크게 기여하고 있습니다.
세계 궤양성 대장염 시장의 성장요인
궤양성 대장염의 증상과 진단에 대한 전 세계적인 인식이 높아짐에 따라, 효과적인 치료법에 대한 수요가 크게 증가하고 있습니다. 그 결과, 각 제약사는 연구 개발에 대한 투자를 강화하도록 장려받고 있습니다. 의료 종사자들은 조기 개입에 중점을 둔 최신 치료 지침을 점점 더 많이 채택하고 있으며, 이에 따라 첨단 생물학적 제제 및 저분자 치료제의 적용 대상 환자층이 확대되고 있습니다. 이러한 임상적 관심의 증가는 시장 성장에 유리한 환경을 조성하고, 학술 기관, 생명공학 기업, 규제 당국 간의 협력을 촉진함으로써 제품 개발을 가속화하며, 당분간 성장 잠재력을 강화하는 데 기여할 것입니다.
세계 궤양성 대장염 시장의 제약요인
생물학적 제제의 높은 비용은 의료 제도에 있어 큰 과제가 되고 있습니다. 특히, 경제적 제약으로 인해 환자들의 의료 접근이 저해되고 있는 저소득 지역에서는 그 영향이 두드러집니다. 보험사는 종종 까다로운 보상 조건을 부과하며, 치료 시작을 지연시킬 수 있는 장기간에 걸친 사전 승인 절차가 필요합니다. 그 결과, 의료 종사자들은 가격은 더 저렴하지만 유효성이 낮은 기존 치료법에 의존할 수밖에 없게 되며, 이는 결국 더 새롭고 혁신적인 치료법의 보급을 저해하는 요인이 됩니다. 이러한 가격에 대한 민감도가 높아지면서 시장 성장이 제한되고 있으며, 제조사들은 다양한 의료 환경에서 더 광범위한 보험 적용을 받기 위해 가격 협상 및 제품 가치 입증이라는 복잡한 과제에 직면하고 있어, 결과적으로 시장 발전이 사실상 주춤하고 있습니다.
세계 궤양성 대장염 시장의 동향
세계 궤양성 대장염 시장은 맞춤형 생물학적 제제 치료법의 부상이 특징인 혁신적인 변화를 맞이하고 있습니다. 유전체학 및 바이오마커 규명의 발전으로 인해, 임상의들은 환자의 특정 질환 표현형에 맞춘 고도로 개인화된 치료 계획을 수립할 수 있게 되었습니다. 이러한 정밀 의료 접근법은 관해율을 높일 뿐만 아니라, 부작용을 최소화함으로써 치료의 새로운 기준을 확립하고 있습니다. 그 결과, 각 제약사는 대상 환자 하위 그룹에 맞춰 신속하게 조정할 수 있는 모듈식 생물학적 제제 플랫폼 개발에 점점 더 주력하고 있습니다. 이러한 변화는 치료의 개별화 중요성을 부각시키고 있으며, 기존의 광범위한 치료법이 아닌 환자 개개인에 맞춘 효능에 기반한 차별화가 요구되는 경쟁 구도를 조성하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 궤양성 대장염 시장 규모 : 약물 계열별
세계의 궤양성 대장염 시장 규모 : 질환 중증도 범위별
세계의 궤양성 대장염 시장 규모 : 유통 채널별
세계의 궤양성 대장염 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.07.22Global Ulcerative Colitis Market size was valued at USD 9.57 Billion in 2024 and is poised to grow from USD 10.39 Billion in 2025 to USD 20.06 Billion by 2033, growing at a CAGR of 8.57% during the forecast period (2026-2033).
The global ulcerative colitis market encompasses the sale of medications, diagnostics, and supportive services aimed at treating this chronic inflammatory bowel disease affecting a significant population. Rising prevalence, high treatment costs, and unmet needs drive market importance. The increasing incidence is largely influenced by urban lifestyles, dietary shifts, and an aging demographic. Advances in diagnostic technology, such as endoscopic imaging and biomarker analysis, facilitate better case detection and a tendency among clinicians to favor biologics over traditional steroids. The emergence of oral small-molecule agents provides additional treatment options, enhancing patient access while reducing infusion burdens. Moreover, AI-driven diagnostics improve early detection and personalized treatment, fostering more effective decision-making and potential for improved outcomes, thereby significantly contributing to market growth and expansion strategies.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ulcerative Colitis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Ulcerative Colitis Market Segments Analysis
Global ulcerative colitis market is segmented by drug class, disease severity range, distribution channel and region. Based on drug class, the market is segmented into Biologics, Small Molecule Target Therapies, Aminosalicylates, Corticosteroids, Immunomodulators and Others. Based on disease severity range, the market is segmented into Mild Ulcerative Colitis, Moderate Ulcerative Colitis and Severe Ulcerative Colitis. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Specialty Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Ulcerative Colitis Market
The growing global awareness surrounding ulcerative colitis symptoms and their diagnosis is significantly boosting the demand for effective treatments. As a result, pharmaceutical companies are motivated to enhance their investments in research and development. Healthcare providers are increasingly adopting modern treatment guidelines that focus on early intervention, which broadens the pool of patients who qualify for advanced biologics and small-molecule therapies. This intensified clinical attention nurtures a favorable landscape for market growth, promoting partnerships among academic institutions, biotech companies, and regulatory agencies, thus expediting product development and strengthening growth potential for the foreseeable future.
Restraints in the Global Ulcerative Colitis Market
The high cost of biologic medications presents a major challenge for healthcare systems, particularly in lower-income regions where financial limitations hinder patient accessibility. Insurance providers often impose stringent reimbursement conditions, necessitating lengthy prior authorization procedures that can postpone the commencement of treatment. As a result, healthcare professionals may resort to utilizing traditional therapies that are more affordable but less effective, which ultimately hampers the acceptance of newer, more innovative options. This heightened price sensitivity restricts market growth, as manufacturers face the complexity of negotiating pricing and demonstrating the value of their products to obtain wider coverage in various healthcare environments, effectively slowing market progression.
Market Trends of the Global Ulcerative Colitis Market
The global ulcerative colitis market is experiencing a transformative trend characterized by the rise of personalized biologic therapies. Advances in genomics and biomarker identification are enabling clinicians to create highly individualized treatment plans tailored to the specific phenotypes of patients' diseases. This precision-medicine approach not only enhances remission rates but also minimizes adverse events, setting a new standard in care. Consequently, pharmaceutical companies are increasingly focusing on developing modular biologic platforms that can be quickly adjusted for targeted patient subsets. This shift emphasizes the importance of therapeutic personalization, fostering a competitive landscape where differentiation is based on tailored efficacy rather than traditional broad-spectrum treatments.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Ulcerative Colitis Market Size by Drug Class & CAGR (2026-2033)
- Market Overview
- Biologics
- Anti-TNF Alpha Agents
- Anti-Integrin Monoclonal Antibodies
- Interleukin Inhibitors
- Small Molecule Target Therapies
- JAK Inhibitors
- S1P Receptor Modulators
- Aminosalicylates
- Corticosteroids
- Immunomodulators
- Others
Global Ulcerative Colitis Market Size by Disease Severity Range & CAGR (2026-2033)
- Market Overview
- Mild Ulcerative Colitis
- Moderate Ulcerative Colitis
- Severe Ulcerative Colitis
Global Ulcerative Colitis Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Specialty Pharmacies
Global Ulcerative Colitis Market Size & CAGR (2026-2033)
- North America (Drug Class, Disease Severity Range, Distribution Channel)
- US
- Canada
- Europe (Drug Class, Disease Severity Range, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Class, Disease Severity Range, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Class, Disease Severity Range, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Class, Disease Severity Range, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- AbbVie
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Holding
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
